Lineage, Inc. Common Stock (LINE)vsVistra Corp. (VST)
LINE
Lineage, Inc. Common Stock
$39.96
-0.03%
REAL ESTATE · Cap: $10.02B
VST
Vistra Corp.
$147.72
-4.05%
UTILITIES · Cap: $52.12B
Smart Verdict
WallStSmart Research — data-driven comparison
Vistra Corp. generates 231% more annual revenue ($17.74B vs $5.36B). VST leads profitability with a 5.3% profit margin vs -2.7%. VST earns a higher WallStSmart Score of 53/100 (C-).
LINE
Hold39
out of 100
Grade: F
VST
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+75.9%
Fair Value
$161.27
Current Price
$39.96
$121.31 discount
Margin of Safety
-52.8%
Fair Value
$101.40
Current Price
$147.72
$46.32 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Areas to Watch
0.4% revenue growth
0.0% earnings growth
Operating margin of 3.3%
ROE of -1.8% — below average capital efficiency
Trading at 19.1x book value
5.3% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : VST
The strongest argument for VST centers on Market Cap. Revenue growth of 13.6% demonstrates continued momentum. PEG of 1.38 suggests the stock is reasonably priced for its growth.
Bear Case : LINE
The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : VST
The primary concerns for VST are Price/Book, Profit Margin, Piotroski F-Score. A P/E of 70.6x leaves little room for execution misses. Debt-to-equity of 3.36 is elevated, increasing financial risk.
Key Dynamics to Monitor
LINE profiles as a turnaround stock while VST is a value play — different risk/reward profiles.
VST is growing revenue faster at 13.6% — sustainability is the question.
VST generates stronger free cash flow (156M), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VST scores higher overall (53/100 vs 39/100) and 13.6% revenue growth. LINE offers better value entry with a 75.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm focused on regenerative medicine, specifically developing cutting-edge cell therapy solutions for treating debilitating conditions, including ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust network of strategic collaborations, Lineage is poised to transform patient care through innovative therapeutic interventions. The company's commitment to advancing its diverse product pipeline and expediting clinical research positions it as an attractive investment opportunity for institutional investors seeking to engage in the forefront of healthcare advancements.
Visit Website →Vistra Corp.
UTILITIES · UTILITIES - INDEPENDENT POWER PRODUCERS · USA
Vistra Corp. The company is headquartered in Irving, Texas.
Visit Website →Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?